Evidence map›Paper›PMID 36148180›Full record

ArticleCureus2022

Myocardial Infarction As the Initial Presentation of Rituximab-Induced Interstitial Lung Disease: A Case Report.

Mohamed Mahmoud, Arshan A Khan, Khadija El Kortbi, Hayoung Wang, Joseph Wang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Mohamed MahmoudInternal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA.
Arshan A KhanInternal Medicine, Ascension Saint John Hospital, Grosse Pointe, USA.
Khadija El KortbiGeneral Practice, Hassan II University, Casablanca, MAR.
Hayoung WangMedicine, University of the Incarnate Word School of Osteopathic Medicine, San Antonio, USA.
Joseph WangInternal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, USA.
St. John Hospital & Medical Center · USUniversity of the Incarnate Word · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab has been widely used alone or in combination therapy to treat B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and various autoimmune diseases. Although it is a relatively safe drug, rare rituximab-induced interstitial lung disease (RTX-ILD) has been reported and can be potentially fatal. Here, we report a patient with stage 4 mantle cell lymphoma on rituximab who presented with non-ST segment elevation myocardial infarction in the setting of severe respiratory distress. He underwent left heart catheterization that revealed no new obstructive lesions and patent grafts. Extensive Infectious and autoimmune workup was negative except for

Indexed as

acute hypoxemic respiratory failurechemotherapy-related toxicitydrug induced interstitial lung diseasesground-glass opacitiesinterstitial pneumonialymphomanon-st elevated myocardial infarctionpneumocystis jiroveci pneumoniarituximab therapystenotrophomonas maltophilia

Identifiers

PMID36148180
PMCPMC9482808
OpenAlexW4292552276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.